Takashi Ito

Dr. Takashi Ito


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Virological Methods
Verified
Journal Article
Closed access
YYYosuke Yasui
Yosuke Yasui
YYYoshiaki Yamaji
Yoshiaki Yamaji
ASAkihito Sawada
Akihito Sawada
TITakashi Ito
Takashi Ito
TNTetsuo Nakayama
Tetsuo Nakayama

22 November 2025 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YKYukako Kosaka
Yukako Kosaka
TITakashi Ito
Takashi Ito
KHKyoko Hattori
Kyoko Hattori
ASAyumi Saito
Ayumi Saito
YOYusuke Okuda
Yusuke Okuda
TNTetsuo Nakayama
Tetsuo Nakayama

29 June 2024 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
KNKyohei Naomiya
Kyohei Naomiya
TITakashi Ito
Takashi Ito
ASAyumi Saito
Ayumi Saito
TITsukasa Igarashi
Tsukasa Igarashi
TNTetsuo Nakayama
Tetsuo Nakayama
KIKenji Ishikura
Kenji Ishikura
Hand, foot, and mouth disease (HFMD) is a common infectious disease caused by enteroviruses. Coxsackievirus A6 (CV-A6)-associated HFMD has recently emerged as a predominant disease worldwide. Here, we describe five HFMD cases caused by CV-A6 in Japan from 2019 to 2022. All clinical courses were not severe and were self-limited, and the skin exanthema with vesicles differed from that in classical HFMD. Phylogenetic analysis showed that the major epidemic strain cluster of CV-A6 was formed independently in 2011, and our latest CV-A6 strains in Japan were detected within this cluster. The five cases described in this report indicate the recent shift in the predominant and continuous disease manifestation of CV-A6-associated HFMD.

2 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
TNTetsuo Nakayama
Tetsuo Nakayama
TITakashi Ito
Takashi Ito
RIRyoka Ishiyama
Ryoka Ishiyama
Kazuhiko KatayamaKazuhiko Katayama
Kazuhiko Katayama
A recombinant SARS-CoV-2 spike protein vaccine (NVX-CoV2373) has been licensed and has a lesser incidence of adverse events. To know the immunological mechanisms of adverse events, the production of cytokines and chemokines was investigated in mice inoculated with NVX-CoV2373. Serum IL-6 was detected on Day 1 of the first and second doses and the IFN-γ, IL-4, IL-10, TNF-α, and IL-6 levels increased on Day 1 of the second dose at the inoculation site. The enhanced production of the inflammatory chemokines (CCL2), homeostatic chemokine (CXCL13), and Th2 chemokine (CCL17) was observed at the inoculation site on Day 1 of the second dose. These findings were compared with data obtained following inoculation with BNT162b2 bivalent vaccine containing omicron BA.4/5. Significantly lower levels of inflammatory chemokines were detected on Day 1 after the first dose of NVX-CoV2373 in sera and inoculation site than those following inoculation with bivalent BNT162b2 (p < 0.01), reflecting a lower incidence of adverse events after immunization with NVX-CoV2373 in humans. NVX-CoV2373 induced significantly higher concentrations of IFN-γ, TNF-α, and IL-10 at the inoculation site obtained on Day 1 of the second dose (p < 0.05). Significant higher levels of Th2 chemokines, CCL11 and CCL17, were induced at the inoculation site on Day 1 of the second dose (p < 0.01) and they explain the booster IgG EIA antibody response after the second dose of NVX-CoV2373.

22 November 2023 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
TNTetsuo Nakayama
Tetsuo Nakayama
RTReiko Todaka
Reiko Todaka
ASAkihito Sawada
Akihito Sawada
TITakashi Ito
Takashi Ito
MFMotoko Fujino
Motoko Fujino
Kazuhiko KatayamaKazuhiko Katayama
Kazuhiko Katayama

22 August 2025 in Vaccine
Verified
Journal Article
Closed access
TITakashi Ito
Takashi Ito
YYYoshiaki Yamaji
Yoshiaki Yamaji
ASAkihito Sawada
Akihito Sawada
TNTetsuo Nakayama
Tetsuo Nakayama